Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence

Autor: Renzi S, Michaeli O, Salvador-Hernandez H, Alderete D, Ponce NF, Zapotocky M, Hansford JR, Malalasekera VS, Toledano H, Maguire B, Bouffet E, Ramaswamy V, Baroni LV

Publikováno v: PEDIATRIC BLOOD & CANCER
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::29358d093473ae42ed110cca94211ac8
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17463

Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia.

Autor: Ellis JA; Royal Children's Hospital, Melbourne, Australia.; Victorian Comprehensive Cancer Centre, Melbourne, Australia., Malalasekera VS; Royal Children's Hospital, Melbourne, Australia.; ONTrac at PeterMac, Victorian Adolescent and Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, Australia., Allan C; Cancer Council Victoria, Melbourne, Australia., Choong PF; Department of Orthopaedics, St. Vincent's Hospital, Melbourne, Australia.; Department of Surgery, The University of Melbourne, Melbourne, Australia.; Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Australia., Hansford JR; Department of Paediatrics, The University of Melbourne, Melbourne, Australia.; Murdoch Children's Research Institute, Melbourne, Australia.; Department of Molecular and Translational Science, Hudson Institute, Monash University, Melbourne, Australia., Hehir R; Royal Children's Hospital, Melbourne, Australia., Morello N; Victorian Comprehensive Cancer Centre Consumer Representative, Melbourne, Australia., O'Callaghan S; Orygen, Melbourne, Australia., Orme L; Royal Children's Hospital, Melbourne, Australia.; ONTrac at PeterMac, Victorian Adolescent and Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, Australia.; Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia., Phillipson N; Royal Children's Hospital, Melbourne, Australia., Rosenthal MA; Victorian Comprehensive Cancer Centre, Melbourne, Australia.; Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia., Sawyer S; Royal Children's Hospital, Melbourne, Australia.; Department of Paediatrics, The University of Melbourne, Melbourne, Australia.; Murdoch Children's Research Institute, Melbourne, Australia., Strong R; Australian and New Zealand Children's Haematology/Oncology Group., Super L; Royal Children's Hospital, Melbourne, Australia.; Monash Children's Hospital, Melbourne, Australia.; Department of Paediatrics, Monash University, Melbourne, Australia., Watt A; Office for Research, Melbourne Health, Melbourne, Australia., Williams C; Royal Children's Hospital, Melbourne, Australia.; Paediatric Integrated Cancer Service, Melbourne, Australia., Woollett A; Victorian Comprehensive Cancer Centre, Melbourne, Australia., Robertson A; Royal Children's Hospital, Melbourne, Australia.; Murdoch Children's Research Institute, Melbourne, Australia., Lewin J; ONTrac at PeterMac, Victorian Adolescent and Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, Australia.; Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

Publikováno v: Journal of adolescent and young adult oncology [J Adolesc Young Adult Oncol] 2022 Apr; Vol. 11 (2), pp. 173-180. Date of Electronic Publication: 2021 Jul 22.

Bevacizumab for pediatric radiation necrosis.

Autor: Baroni LV; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina.; Arthur and Sonia Labatt Brain Tumour Research Centre, Programme in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada., Alderete D; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina., Solano-Paez P; Service of Pediatric Oncology, Hospital Infantil Virgen del Rocío, Seville, Spain., Rugilo C; Service of Diagnostic Imaging, Hospital JP Garrahan, Buenos Aires, Argentina., Freytes C; Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina., Laughlin S; Department of Diagnostic Imaging, Hospital for Sick Children, Toronto, ON, Canada., Fonseca A; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada., Bartels U; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada., Tabori U; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Bouffet E; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada., Huang A; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Laperriere N; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Tsang DS; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Sumerauer D; Department of Paediatric Haematology and Oncology, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic., Kyncl M; Department of Radiology, University Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic., Ondrová B; Proton Therapy Center Czech, Prague, Czech Republic., Malalasekera VS; Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia., Hansford JR; Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia.; Division of Cancer, Murdoch Children's Research Institute, Melbourne, Australia.; Department of Paediatrics, University of Melbourne and Monash University, Melbourne, Australia., Zápotocký M; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada., Ramaswamy V; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Arthur and Sonia Labatt Brain Tumour Research Centre, Programme in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

Publikováno v: Neuro-oncology practice [Neurooncol Pract] 2020 Jul; Vol. 7 (4), pp. 409-414. Date of Electronic Publication: 2020 Jan 20.